Navigation Links
Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
Date:10/17/2007

GAITHERSBURG, Md., Oct. 17 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. announced today that BC Detect(SM), the Company's serum-based breast cancer diagnostic test, is now available from Panacea Laboratories. BC Detect(SM) is a simple blood test that should facilitate the identification of recurrence among women successfully treated for breast cancer. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample can be ordered by any physician and sent to Panacea for testing; sample and shipping requirements are available at http://www.panacea-labs.com.

Breast cancer is the most common type of cancer in women accounting for 26% of female cancers. One in every eight women will develop breast cancer in their lifetime, placing the lifetime risk at 13%. More than 200,000 new cases of breast cancer will be diagnosed in the United States in 2007 and upwards of 2 million women are currently breast cancer survivors. Five-year survival rates for breast cancer are 98% for localized disease, 83% for regionally spread and 26% for distantly spread cancer. However, 25% of all metastases occur more than 5 years after the initial diagnosis and thus survival rates decrease as time goes out to 10 years due to disease recurrence. Methods to detect initial presentation of breast cancer as well as recurrence rely on imaging modalities, including mammography and MRI. No serum biomarkers have been approved for either primary breast cancer screening or monitoring for disease recurrence primarily due to relatively low specificities and sensitivities. In asymptomatic women in remission from breast cancer the guidelines of the major oncologic organizations only suggest annual mammography for detection of new tumors.

BC Detect(SM) measures levels of human aspartyl (asparaginyl) beta- hydroxylase (HAAH), a cancer molecular
'/>"/>

SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Kerr Corporation, ... 10-minute video and additional how-to information about dual arch impressions ... Restorations with Dual Arch Impressions,” the blog entry serves up ... technique and houses a step-by-step demonstration by Dr. David Little ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... /PRNewswire/-- RoundTable Healthcare,Partners, an operating-oriented private ... industry, announced that it has completed ... to an affiliate of Firstsource,Solutions Limited ... Mumbai-based,Firstsource (NSE: FSL.NS, BSE: FSL.BO) is ...
... of every day, someone dies,of melanoma in the United States, ... U.S. and worldwide. Since 1975, the incidence rate,of new melanomas ... economic levels and both sexes. Currently, there are more new,cases ... melanoma is,found early there is an excellent chance of recovery. ...
... WESTFORD, Mass., Sept. 28 Cynosure, Inc.,(Nasdaq: ... a broad array of,light-based aesthetic treatment systems, today ... Swann & Company/MEDACorp Aesthetics Roundtable,Conference. Chief Financial ... strategy and recent financial results in a presentation,beginning ...
Cached Biology Technology:RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited 2RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited 3Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers 2Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference 2
(Date:4/23/2014)... from the Indiana University School of Public Health-Bloomington has ... disease by finding a strong association between heme iron, ... disease. , The study found that heme iron consumption ... percent, while no association was found between nonheme iron, ... coronary heart disease. , The study was published online ...
(Date:4/23/2014)... that male black widow spiders prefer their female mates ... mate preference by male spiders. , The ... Andrade, a professor in UTSC,s Department of Biological Sciences, ... that males overwhelmingly chose to mate with well-fed, unmated ... whether a potential mate is well-fed and unmated by ...
(Date:4/23/2014)... trope that the likelihood of an accurate group decision ... hold up when a collective faces a variety of ... Instead, Princeton University researchers report that smaller groups actually ... may become excessively focused on only certain pieces of ... what is known about collective intelligence, or the "wisdom ...
Breaking Biology News(10 mins):Study: Iron consumption can increase risk for heart disease 2Picky male black widow spiders prefer well-fed virgins 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... it seems, even in,science. A team led by Johns ... information in order to build a protein,only to find ... of experiments, the scientists found that when yeast's,protein-building machinery ... alters its structure and then releases a factor,known as ...
... Many rivers and streams in the United States,are ... fate was never thoroughly scrutinized despite large scale,production ... to an,analysis conducted by researchers at the Johns ... has been widely used for,decades in hand soaps ...
... Brain cells in a mouse model of Alzheimer's,disease ... the disorder's characteristic brain plaques are removed.,Researchers at ... mice with an antibody for a key component ... areas of the brain where,antibodies cleared plaques, many ...
Cached Biology News:Timing is everything: First step in protein building revealed 2Timing is everything: First step in protein building revealed 3Anti-bacterial additive widespread in U.S. waterways 2Key molecule in plant photo-protection identified 2Key molecule in plant photo-protection identified 3
Procollagen type I C-terminal propeptide (human, PICP)...
... in Early Drug Development with Imaging Mass ... drug compound localization data in early drug ... mass spectrometry service maps unlabeled ... so you can localize drugs and metabolites ...
... LC Sciences provides a unique new ... DNA synthesis serving diverse needs in genomics, ... applications. OligoMix is a MIXTURE of a ... sequences delivered in a single microtube. OligoMix ...
... is an automated, high-resolution protein analysis ... ProteomeLab family of products, the PA ... automated protein characterization solutions including molecular ... carbohydrate profiling and mechanisms to study ...
Biology Products: